This result suggested that allo‐HSCT may be an effective way to overcome the adverse impact of SMIM3. Collectively, these results suggested that SMIM3 might be a novel prognostic marker for NK-AML patients. This evidence concerns the gene SMIM3 and acute myeloid leukemia.